期刊文献+

Response surface analysis of sevoflurane-remifentanil interactions on consciousness during anesthesia 被引量:3

Response surface analysis of sevoflurane-remifentanil interactions on consciousness during anesthesia
原文传递
导出
摘要 Background Recently, the combination of sevoflurane and remifentanil has been widely used in general anesthesia. In this study, we investigated the sevoflurane-remifentanil pharmacodynamic interactions at clinical concentrations using the observer's assessment of alertness/sedation (OAA/S) and the bispectral index (BIS) by response surface analysis. Methods Totally 65 American Society of Anesthesiologists (ASA) I patients age 20 to 50 years old were included in this study. Patients were randomly assigned to be anesthetized with different target end-tidal sevoflurane concentrations that ranged from 0.2% to 3.4% in increments of 0.2%. The end-tidal sevoflurane concentration was maintained constant throughout the study. Remifentanil was infused with a target controlled infusion (TCI) system at increasing step-wise concentrations from 1 ng/ml to 10 ng/ml. The values of OAA/S and BIS at different sevoflurane-remifentanil concentration combinations were measured. The pharmacodynamic interactions between sevoflurane and remifentanil were analyzed by a response surface method. The three-dimensional response surfaces were constructed with Minitab Software. Model parameters were estimated with NONMEM program. Results Sevoflurane and remifentanil acted synergistically on OANS. Sevoflurane alone could produce OANS 〈1 at a minimal alveolar concentration (MAC) of 0.93%. When used in combination with remifentanil at 1, 3, 6, and 10 ng/ml, the corresponding sevoflurane MACs were reduced to 0.79%, 0.58%, 0.48%, and 0.38%, with reductions of 17.2%, 37.6%, 48.4%, and 62.0% from baseline, respectively. In patients administered remifentanil alone, the OANS score was 〉3 even when the remifentanil concentration reached 10 ng/ml. BIS was closely associated with the sevoflurane concentration and the remifentanil concentration did not noticeably influence the relationship between the sevoflurane concentration and BIS. A sevoflurane concentration of (1.04+0.19)% to (1.81+0.21)% could maintain a BIS between 60 and 40. Conclusions The response surface method can analyze the pharmacodynamic interactions between remifentanil and sevoflurane qualitatively and quantitatively. Within the range of our study (remifentanil 〈10 ng/ml, sevoflurane 〈3.4%), the two drugs produced synergistic effects on OAA/S but had no interactive effect on BIS. A guideline of BIS between 40 and 60 may cause excessive anesthesia when opioids are used to maintain anesthesia. Background Recently, the combination of sevoflurane and remifentanil has been widely used in general anesthesia. In this study, we investigated the sevoflurane-remifentanil pharmacodynamic interactions at clinical concentrations using the observer's assessment of alertness/sedation (OAA/S) and the bispectral index (BIS) by response surface analysis. Methods Totally 65 American Society of Anesthesiologists (ASA) I patients age 20 to 50 years old were included in this study. Patients were randomly assigned to be anesthetized with different target end-tidal sevoflurane concentrations that ranged from 0.2% to 3.4% in increments of 0.2%. The end-tidal sevoflurane concentration was maintained constant throughout the study. Remifentanil was infused with a target controlled infusion (TCI) system at increasing step-wise concentrations from 1 ng/ml to 10 ng/ml. The values of OAA/S and BIS at different sevoflurane-remifentanil concentration combinations were measured. The pharmacodynamic interactions between sevoflurane and remifentanil were analyzed by a response surface method. The three-dimensional response surfaces were constructed with Minitab Software. Model parameters were estimated with NONMEM program. Results Sevoflurane and remifentanil acted synergistically on OANS. Sevoflurane alone could produce OANS 〈1 at a minimal alveolar concentration (MAC) of 0.93%. When used in combination with remifentanil at 1, 3, 6, and 10 ng/ml, the corresponding sevoflurane MACs were reduced to 0.79%, 0.58%, 0.48%, and 0.38%, with reductions of 17.2%, 37.6%, 48.4%, and 62.0% from baseline, respectively. In patients administered remifentanil alone, the OANS score was 〉3 even when the remifentanil concentration reached 10 ng/ml. BIS was closely associated with the sevoflurane concentration and the remifentanil concentration did not noticeably influence the relationship between the sevoflurane concentration and BIS. A sevoflurane concentration of (1.04+0.19)% to (1.81+0.21)% could maintain a BIS between 60 and 40. Conclusions The response surface method can analyze the pharmacodynamic interactions between remifentanil and sevoflurane qualitatively and quantitatively. Within the range of our study (remifentanil 〈10 ng/ml, sevoflurane 〈3.4%), the two drugs produced synergistic effects on OAA/S but had no interactive effect on BIS. A guideline of BIS between 40 and 60 may cause excessive anesthesia when opioids are used to maintain anesthesia.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第15期2682-2687,共6页 中华医学杂志(英文版)
基金 The National Natural Science Foundation Youth Fund of China
关键词 SEVOFLURANE REMIFENTANIL response surface the observer's assessment of alertness/sedation bispectral index sevoflurane remifentanil response surface, the observer's assessment of alertness/sedation bispectral index
  • 相关文献

参考文献22

  • 1Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. Response surface model for anesthetic drug interactions. Anesthesiology 2000; 92: 1603-1616.
  • 2Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.
  • 3Wang HL, Yang L, Guo XY, Pharmacodynamic interaction Zhang LP, Bi SS, Lu W. between sevoflurane and remifentanil regarding tolerance of responses to electrical tetanus stimuli. Chin J New Drugs (Chin) 2011; 21: 902-905.
  • 4Short TG, Ho TY, Minto CF, Schnider TW, Shafer SL. Efficient trial design for eliciting a pharmacokinetic- pharmacodynamic model-based response surface describing the interaction between two intravenous anesthetic drug. Anesthesiology 2002; 96: 400-408.
  • 5Wei SL, Zhang Q. Biopharmaceutics and pharmacokinetics. 2nd ed. Beijing: Peking University Medical Press; 2004: 238-271.
  • 6Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865-872.
  • 7Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, et al. Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. Anesthesiology 2006; 105: 267-278.
  • 8Manyam SC, Gupta DK, Johnson KB, White JL, Pace NL, Westenskow DR, et al. When is a bispectral index of 60 too low? rational processed electroencephalographic targets are dependent on the sedative-opioid ratio. Anesthesiology 2007; 106: 472-483.
  • 9Johnson KB, Syroid ND, Gupta DK, Manyam SC, Egan TD, Huntington J, et al. An evaluation of remifemanil propofol response surfaces for loss of responsiveness, loss of response to surrogates of painful stimuli and laryngoscopy in patients undergoing elective surgery. Anesth Analg 2008; 106: 471-479.
  • 10Mertens MJ, Olofsen E, Engbers FH, Burm AG, Bovill JG,Vuyk J. Propofol reduces perioperative remifentanil requirements in a synergistic manner. Anesthesiology 2003; 99: 347-359.

同被引文献7

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部